scispace - formally typeset
J

James R. Runo

Researcher at University of Wisconsin-Madison

Publications -  15
Citations -  572

James R. Runo is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Pulmonary hypertension & Portopulmonary hypertension. The author has an hindex of 6, co-authored 15 publications receiving 433 citations. Previous affiliations of James R. Runo include University of Wisconsin Hospital and Clinics.

Papers
More filters
Journal ArticleDOI

BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia

TL;DR: The genetic etiology for 191 unrelated individuals clinically suspected to have HHT was investigated with the use of exome and Sanger sequencing and bmp9-deficient zebrafish model demonstrated that BMP9 is involved in angiogenesis, confirming a genetic cause of a vascular-anomaly syndrome that has phenotypic overlap with HHT.
Journal ArticleDOI

Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension

TL;DR: An aggressive approach to the treatment of PoPH with sildenafil and/or treprostinil and subsequent liver transplantation may be curative for PoPH in some patients.
Journal ArticleDOI

Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients

TL;DR: Two patients with no family history of HHT and strikingly different clinical presentations, who are mosaic for mutations in the ACVRL1 or ENG gene, are reported here, which represents the first report of mosaicism in patients clinically affected with classical H HT and pulmonary arterial hypertension.
Journal ArticleDOI

Magnetic Resonance and Computed Tomography Imaging of the Structural and Functional Changes of Pulmonary Arterial Hypertension

TL;DR: Although features that are indirectly related to PAH are found on noninvasive imaging studies, its diagnosis and management still require right heart catheterization, andUntreated PAH frequently results in rapid clinical decline and death within 3 years of diagnosis.